NCT04790175 - Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

August 31, 2028

Study Completion Date

January 31, 2030

Conditions

Antidiuretic Hormone, Inappropriate Secretion

Interventions

DRUG

Tolvaptan (SAMSCA)

The usual adult dose of SAMSCA is 7.5 mg of tolvaptan once daily administered orally, increased stepwise to 60 mg daily until a desirable level of serum sodium concentration is achieved.

Trial Locations (1)

540-0021

RECRUITING

Pharmacovigilance Department, Osaka